Lynch-associated bladder cancers are usually MMR-deficient; thus, as with UTUC, any urothelial tumor in a known Lynch patient warrants MMR analysis, and eligible patients with advanced disease may receive immunotherapy [55,59]. The gene discussed is MRC1; the disease is urinary bladder cancer.